Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the GLP-1 Receptor Agonist Market Size Changed, over the years?

In recent times, the market size for GLP-1 receptor agonist has been expanding progressively. The market is anticipated to increase from $13.58 billion in 2024 to $14.22 billion in 2025 with a compound annual growth rate (CAGR) of 4.7%. The expansion during the historical phase can be ascribed to factors such as escalating prevalence of diabetes, clinical effectiveness, patient understanding and approval, global health campaigns, and patient inclination towards injectable treatments.

How Much Will the GLP-1 Receptor Agonist Market Be Worth in 2029?

In the coming years, the GLP-1 receptor agonist market is projected to witness significant growth, reaching a valuation of $17.72 billion by 2029, exhibiting a compound annual growth rate of 5.7%. Various factors driving this growth during the forecast period encompass a heightened focus on managing lifestyle, the rise of personalized medical treatments, broader indications, the development of innovative next-gen products, and their integration into combination therapies. Further trends that will define the forecast period include the emergence of oral formulations, an increased concentration on combination therapies, forming key partnerships and collaborations, refining reimbursement policies and accessibility, and adopting more patient-centric tactics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

Which is the Largest Company in the GLP-1 Receptor Agonist Market?

Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG

What Are the Main Market Drivers in the GLP-1 Receptor Agonist Industry?

The increasing incidence of diabetes is predicted to boost the GLP-1 receptor agonist market. Diabetes, a chronic condition, arises when the pancreas either secretes inadequate insulin or when the body fails to efficiently use the insulin it generates. The telltale sign of diabetes mellitus, a metabolic disorder, is elevated blood sugar. The use of GLP-1 receptor agonist in diabetes prompts your body to secrete more insulin, thereby reducing blood sugar levels. As a result, the escalating incidence of diabetes is likely to fuel market growth. For example, in March 2024, the UK’s Office for Health Improvement and Disparities reported that between March 2022 and March 2023, the proportion of type 1 diabetes patients undergoing all eight recommended care processes rose by 22%. Meanwhile, for type 2 diabetes, this figure increased by 21%. Furthermore, the proportion reaching the target HbA1c levels escalated to 37.9%, the most significant figure the National Diabetes Audit (NDA) has ever documented. Therefore, the growing occurrence of diabetes is stimulating the GLP-1 receptor agonist market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9631&type=smp

How Is the GLP-1 Receptor Agonist Market Segments Structured?

The GLP-1 receptor agonist market covered in this report is segmented –

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs

2) By Route Of Administration: Parenteral, Oral

3) By End Users: Hospitals, Surgical Clinics, Other Users

Subsegments:

1) By Exenatide: Byetta, Bydureon

2) By Liraglutide: Victoza, Saxenda

3) By Dulaglutide: Trulicity

4) By Lixisenatide: Adlyxin

5) By Other Drugs: Semaglutide, Tirzepatide, Others

What Strategic Trends Are Transforming the GLP-1 Receptor Agonist Market?

In the GLP-1 receptor agonist market, a primary trend that is gaining traction is product innovation. Major firms in the sector are concentrating on creating innovative solutions to consolidate their market position. For example, Eli Lilly and Company, a pharmaceutical company based in the US committed to improving lives through medicine, launched Mounjaro, a GIP and GLP-1 receptor agonist approved by the FDA, in May 2022. Mounjaro is uniquely engineered with a singular molecule that activates the body’s incretin hormones GIP and GLP-1 receptors. It’s available as an auto-injector pen featuring a pre-fitted, concealed needle that doesn’t require patient handling or visibility, and it’s offered in 6 different doses.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

Which Global Regions Offer the Highest Growth in the GLP-1 Receptor Agonist Market?

North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9631

This Report Delivers Insight On:

1. How big is the glp-1 receptor agonist market, and how is it changing globally?

2. Who are the major companies in the glp-1 receptor agonist market, and how are they performing?

3. What are the key opportunities and risks in the glp-1 receptor agonist market right now?

4. Which products or customer segments are growing the most in the glp-1 receptor agonist market?

5. What factors are helping or slowing down the growth of the glp-1 receptor agonist market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model